SWE ORPHAN BIOVITRU (B6E BE) stock market data APIs
€25.0097
0(0%)
as of July 4, 2025
Try our APIs with
free plan!
SWE ORPHAN BIOVITRU Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for B6E.BE.
Prev. Close
25.0097
Open
25.0097
High
25.0097
Low
25.0097
52 wk Range
22.72-30.56
Market Cap
5 414 M
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SWE ORPHAN BIOVITRU data using free add-ons & libraries
Get SWE ORPHAN BIOVITRU Fundamental Data
SWE ORPHAN BIOVITRU Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SWE ORPHAN BIOVITRU News
New
Invitation: Sobi's Q2 report
Sobi plans to publish its report for the second quarter of 2025 on 16 July 2025 at 08:00 CEST. STOCKHOLM, July 2, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited to a conference c...
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obliga...
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8. STOCKHOLM, June 28, 2025 /PRNe...
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
STOCKHOLM, June 20, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will be presenting a wide range of clinical study updates at the annual International Society on Thrombosis and Haemostasis (ISTH) Congress ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
